Vivos Therapeutics Stock Forecast

VVOS's stock price has decreased by -88.29% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

According to 3 analysts polled by S&P Global, Vivos Therapeutics stock has a consensus rating of "Buy" and an average price target of $2.45. The average 1-year stock price forecast is 440.60% higher than the current stock price, while the lowest is $1.75 (+286.14%) and the highest is $3.10 (+584.02%).

Price Target: $2.45 (+440.60%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$1.75	$2.45	$2.50	$3.10
Change	+286.14%	+440.60%	+451.63%	+584.02%

* Price targets were last updated on Jun 4, 2026.

Analyst Ratings

The average analyst rating for Vivos Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	2	2	2	2	2	2
Buy	0	0	0	0	0	0
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Lucas Ward Ascendiant	Ascendiant	Buy Reiterates $3 → $3.1	Buy	Reiterates	$3 → $3.1	+584.02%	Jun 4, 2026
Yi Chen H.C. Wainwright	H.C. Wainwright	Buy Reiterates $2.5	Buy	Reiterates	$2.5	+451.63%	Apr 17, 2026
Scott Henry Alliance Global Partners	Alliance Global Partners	Hold Maintains $2.5 → $1.75	Hold	Maintains	$2.5 → $1.75	+286.14%	Apr 17, 2026

Financial Forecast

Revenue This Year

23.12M

from 17.44M

32.55%

from 17.44M

Revenue Next Year

34.51M

from 23.12M

49.26%

from 23.12M

EPS This Year

-1.82

from -2.07

EPS Next Year

-0.84

from -1.82

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	16.89M	16.02M	13.80M	15.03M	17.44M	23.12M
Revenue Growth	29.23%	-5.10%	-13.87%	8.91%	16.05%	32.55%
Gross Profit	12.60M	10.02M	8.27M	9.02M	10.54M	14.03M
Gross Margin	74.65%	62.52%	59.93%	60.00%	60.44%	60.67%
Operating Income	-19.47M	-25.03M	-17.30M	-11.17M	-19.89M	-23.82M
Net Income	-20.29M	-23.85M	-13.58M	-11.14M	-21.17M	-27.35M
EPS	-	-	-	-	-2.07	-1.82
No. Analysts	-	-	-	-	-	2

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027
High	24.1M
Avg	23.1M
Low	22.1M

Revenue Growth

Revenue Growth	2026	2027
High	38.4%
Avg	32.5%
Low	26.7%

EPS Forecast

EPS	2026	2027
High	-1.50
Avg	-1.82
Low	-2.14

EPS Growth

EPS Growth	2026	2027
High	-
Avg	-
Low	-